JP2019527233A - スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用 - Google Patents

スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用 Download PDF

Info

Publication number
JP2019527233A
JP2019527233A JP2019505213A JP2019505213A JP2019527233A JP 2019527233 A JP2019527233 A JP 2019527233A JP 2019505213 A JP2019505213 A JP 2019505213A JP 2019505213 A JP2019505213 A JP 2019505213A JP 2019527233 A JP2019527233 A JP 2019527233A
Authority
JP
Japan
Prior art keywords
alkyl
group
occurrence
compound
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019505213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527233A5 (enExample
Inventor
カーン，エム．アミン
Original Assignee
アプティニックス インコーポレイテッド
アプティニックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アプティニックス インコーポレイテッド, アプティニックス インコーポレイテッド filed Critical アプティニックス インコーポレイテッド
Publication of JP2019527233A publication Critical patent/JP2019527233A/ja
Publication of JP2019527233A5 publication Critical patent/JP2019527233A5/ja
Priority to JP2022092387A priority Critical patent/JP7448766B2/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019505213A 2016-08-01 2017-08-01 スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用 Pending JP2019527233A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022092387A JP7448766B2 (ja) 2016-08-01 2022-06-07 スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662369453P 2016-08-01 2016-08-01
US62/369,453 2016-08-01
PCT/US2017/044838 WO2018026779A1 (en) 2016-08-01 2017-08-01 Spiro-lactam nmda receptor modulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022092387A Division JP7448766B2 (ja) 2016-08-01 2022-06-07 スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用

Publications (2)

Publication Number Publication Date
JP2019527233A true JP2019527233A (ja) 2019-09-26
JP2019527233A5 JP2019527233A5 (enExample) 2020-09-17

Family

ID=59582038

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019505213A Pending JP2019527233A (ja) 2016-08-01 2017-08-01 スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
JP2022092387A Active JP7448766B2 (ja) 2016-08-01 2022-06-07 スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022092387A Active JP7448766B2 (ja) 2016-08-01 2022-06-07 スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用

Country Status (17)

Country Link
US (3) US11299495B2 (enExample)
EP (1) EP3490992B1 (enExample)
JP (2) JP2019527233A (enExample)
KR (1) KR102465758B1 (enExample)
CN (1) CN109937204B (enExample)
AU (2) AU2017306152A1 (enExample)
BR (1) BR112019001768A2 (enExample)
CA (1) CA3031537A1 (enExample)
CL (1) CL2019000248A1 (enExample)
CO (1) CO2019000945A2 (enExample)
EA (1) EA201990424A1 (enExample)
IL (1) IL264514B (enExample)
MX (1) MX383650B (enExample)
PE (1) PE20190503A1 (enExample)
PH (1) PH12019500202A1 (enExample)
SG (2) SG10202101055VA (enExample)
WO (1) WO2018026779A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512098A (ja) * 2018-01-31 2021-05-13 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
JP2023525860A (ja) * 2020-05-12 2023-06-19 ベイジン・グレートウェイ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド Ｎｍｄａ受容体の活性を調節する化合物、その医薬組成物及び使用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5702288B2 (ja) 2008-09-18 2015-04-15 ノースウエスタン ユニバーシティ Ｎｍｄａレセプターモジュレータ及びその用途
LT2951183T (lt) 2013-01-29 2019-05-27 Aptinyx Inc. Spiro-laktamo nmda receptorių moduliatoriai ir jų panaudojimas
EA201990424A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
PE20190504A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
MX385336B (es) 2016-08-01 2025-03-18 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
AU2017306158B2 (en) 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
ES2974090T3 (es) 2016-08-01 2024-06-25 Tenacia Biotechnology Hong Kong Co Ltd Moduladores de NMDA de espirolactama y métodos de uso de los mismos
AU2019215049A1 (en) * 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CN109608460A (zh) * 2018-12-17 2019-04-12 上海合全药业股份有限公司 一种1,10-二氧亚基-2,7-二氮杂螺[4.5]癸烷-7-甲酸叔丁酯的合成方法
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
CN114591326B (zh) * 2022-02-28 2024-02-27 上海筛杰生物医药有限公司 Cct-251921的中间体及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510711A (ja) * 2004-08-20 2008-04-10 ターガセプト，インコーポレイテッド 嗜癖治療におけるｎ−アリールジアザスピラ環状化合物の使用
US20110159005A1 (en) * 2009-12-04 2011-06-30 Abbott Laboratories 11-beta-hydroxysteroid dehydrogenase type 1 (11beta-hsd1) inhibitors and uses thereof
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
JP2012526154A (ja) * 2009-05-12 2012-10-25 エフ．ホフマン−ラ ロシュ アーゲー Ｈｓｌ阻害薬としてのアザ環式スピロ誘導体
US20130150342A1 (en) * 2010-02-19 2013-06-13 Novartis Ag Pyrrolopyrimidine compounds as inhibitors of cdk4/6
JP2013532125A (ja) * 2010-05-10 2013-08-15 クオンベルゲンセ プハルマセウトイカルス リミテッド カルシウムチャネルに対する親和性を有するスピロ環誘導体
JP2014511826A (ja) * 2011-03-14 2014-05-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾジオキサンインヒビター

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180398A1 (en) 1984-10-26 1986-05-07 The Regents Of The University Of California Synthesis of beta-lactam
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5350769A (en) 1990-10-30 1994-09-27 Ss Pharmaceutical Co., Ltd. Antiinflammatory gel preparation
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
NZ332347A (en) 1996-06-07 2000-05-26 Zeneca Ltd Peptide derivatives containing a hydrophobic group, L-amino acid residues and modified L-amino acid residues
US5959075A (en) 1996-08-02 1999-09-28 Zymogenetics, Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
AU1585999A (en) 1997-11-12 1999-05-31 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
WO2000027790A1 (en) 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Mutilin compounds
AU1724000A (en) 1998-11-12 2000-05-29 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
AU1922301A (en) 1999-11-17 2001-05-30 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
CA2398250A1 (en) 2000-02-01 2001-08-09 Agy Therapeutics, Inc. Interaction of nmda receptor with protein tyrosine phosphatase
JP2001261679A (ja) 2000-03-21 2001-09-26 Mitsui Chemicals Inc ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
WO2001096606A2 (en) 2000-06-14 2001-12-20 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
AU2001271366A1 (en) 2000-06-22 2002-01-02 Nyxis Neurotherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
US20020142287A1 (en) 2000-12-14 2002-10-03 Hirotaka Yamamoto High throughput assay to detect inhibitors of the map kinase pathway
WO2002072005A2 (en) 2001-03-07 2002-09-19 University Of Utah Research Foundation Linear y-carboxyglutamate rich conotoxins
AU2002255705A1 (en) 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
WO2003010540A1 (en) 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Method of identifying nmda-related agent
EA009789B1 (ru) 2002-07-05 2008-04-28 Таргасепт, Инк. N-арилдиазаспирациклические соединения и способы их получения и применения
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
JP2006523704A (ja) 2003-04-17 2006-10-19 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性ヘテロサイクリックシクロペンチルテトラヒドロイソキノリンおよびテトラヒドロピリドピリジンのモジュレーター
CA2573951A1 (en) 2003-07-18 2005-01-27 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
EP1660634A4 (en) 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
WO2005020973A2 (en) 2003-08-29 2005-03-10 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
EP1683797A1 (en) 2003-11-13 2006-07-26 Ono Pharmaceutical Co., Ltd. Heterocyclic spiro compound
BRPI0418375A (pt) 2004-01-08 2007-05-22 Hoffmann La Roche derivados de diaza-espiropiperidina
WO2006034196A1 (en) 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
CN101090902B (zh) 2004-10-13 2013-05-29 默沙东公司 Cgrp受体拮抗剂
EP2030622B1 (en) 2005-03-24 2011-02-23 Emory University Indication of dosage of progesterone in the treatment of a traumatic brain injury
AU2006282942B2 (en) 2005-08-26 2012-07-26 Wisconsin Alumni Research Foundation Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
MX2009002921A (es) 2006-09-15 2009-04-01 Schering Corp Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
JP2008188285A (ja) 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
CN101675041A (zh) 2007-03-20 2010-03-17 沃泰克斯药物股份有限公司 用作激酶抑制剂的氨基嘧啶类化合物
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
US20090054392A1 (en) 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
AU2009217278B2 (en) 2008-02-20 2015-08-20 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
EP2293777B1 (en) 2008-06-24 2015-02-25 Intervet International B.V. Pharmaceutical transdermal compositions and method for treating inflammation in cattle
CN102076679A (zh) 2008-06-27 2011-05-25 神经研究公司 新颖的四甲基取代的哌啶衍生物及其作为单胺神经递质再摄取抑制剂的用途
KR101647520B1 (ko) 2008-08-07 2016-08-10 에프. 호프만-라 로슈 아게 거대환식 화합물의 제조 방법
GB0814991D0 (en) 2008-08-15 2008-09-24 Glaxo Group Ltd Compounds
JP5702288B2 (ja) 2008-09-18 2015-04-15 ノースウエスタン ユニバーシティ Ｎｍｄａレセプターモジュレータ及びその用途
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
DE102009001460B4 (de) 2009-03-11 2010-12-02 Zf Friedrichshafen Ag Ölbehälter
WO2011003064A2 (en) 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
DK2985032T3 (en) 2009-10-05 2019-04-15 Univ Northwestern GLYX TO USE TO TREAT ALZHEIMER'S DISEASE, PARKINSON'S DISEASE OR HUNTINGTON'S DISEASE
EP2516439B1 (en) 2009-12-21 2014-01-22 Novartis AG Diaza-spiro[5.5]undecanes as orexin receptor antagonists
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
AU2011215704B2 (en) 2010-02-11 2015-07-23 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
AR082633A1 (es) 2010-08-12 2012-12-19 Tetraphase Pharmaceuticals Inc Analogos de tetraciclina
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
EA029999B1 (ru) 2011-04-27 2018-06-29 Нортвестерн Юниверсити Способы лечения аутизма
US9293690B2 (en) 2011-06-27 2016-03-22 Koninklijke Philips N.V. Ultrasound transducer assembly and method of manufacturing the same
WO2013010275A1 (en) 2011-07-18 2013-01-24 The Governors Of The University Of Alberta Catalysts and processes for the hydrogenation of amides
MY161925A (en) 2011-07-27 2017-05-15 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
US9546179B2 (en) 2011-12-20 2017-01-17 Wei Qian Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
CN102936216B (zh) 2012-12-05 2015-03-04 南京药石药物研发有限公司 7,9-二氧代-2,6-氮杂-螺[3.5]壬-2-甲酸叔丁酯及其中间体的制备方法
CA2899010A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
LT2951183T (lt) 2013-01-29 2019-05-27 Aptinyx Inc. Spiro-laktamo nmda receptorių moduliatoriai ir jų panaudojimas
MX375286B (es) 2013-01-29 2025-03-06 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
CN103171641B (zh) 2013-03-19 2015-07-15 浙江大学 具备轮动功能的弹跳机器人
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
GB2528480A (en) 2014-07-23 2016-01-27 Givaudan Sa Improvements in or relating to organic compounds
GB201416346D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP6823083B2 (ja) 2016-05-19 2021-01-27 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
EA201990424A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
ES2974090T3 (es) 2016-08-01 2024-06-25 Tenacia Biotechnology Hong Kong Co Ltd Moduladores de NMDA de espirolactama y métodos de uso de los mismos
PE20190504A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
MX385336B (es) 2016-08-01 2025-03-18 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
AU2017306158B2 (en) 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
AU2019215049A1 (en) 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
JP7210599B2 (ja) 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
US20210308101A1 (en) 2019-11-11 2021-10-07 Aptinyx Inc. Methods of treating fibromyalgia
KR20220110251A (ko) 2019-12-04 2022-08-05 앱티닉스 인크. 신경변성 질환과 연관된 인지 장애를 치료하는 방법

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510711A (ja) * 2004-08-20 2008-04-10 ターガセプト，インコーポレイテッド 嗜癖治療におけるｎ−アリールジアザスピラ環状化合物の使用
JP2012526154A (ja) * 2009-05-12 2012-10-25 エフ．ホフマン−ラ ロシュ アーゲー Ｈｓｌ阻害薬としてのアザ環式スピロ誘導体
US20110159005A1 (en) * 2009-12-04 2011-06-30 Abbott Laboratories 11-beta-hydroxysteroid dehydrogenase type 1 (11beta-hsd1) inhibitors and uses thereof
US20130150342A1 (en) * 2010-02-19 2013-06-13 Novartis Ag Pyrrolopyrimidine compounds as inhibitors of cdk4/6
JP2013532125A (ja) * 2010-05-10 2013-08-15 クオンベルゲンセ プハルマセウトイカルス リミテッド カルシウムチャネルに対する親和性を有するスピロ環誘導体
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
JP2014511826A (ja) * 2011-03-14 2014-05-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾジオキサンインヒビター

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF ORGANIC CHEMISTRY, vol. 71, JPN6021020531, 2006, pages 97 - 102, ISSN: 0004517366 *
JOURNAL OF PHARMACY RSEARCH, vol. 5, no. 11, JPN6021020528, 2012, pages 5127 - 5130, ISSN: 0004517365 *
REGISTRY（STN）[ON LINE], JPN6021020521, 7 May 2010 (2010-05-07), ISSN: 0004701364 *
REGISTRY（STN）[ON LINE], JPN6021020523, 28 January 2010 (2010-01-28), ISSN: 0004701365 *
REGISTRY[ON LINE], JPN7022000524, 29 January 2017 (2017-01-29), ISSN: 0004701368 *
REGISTRY[ON LINE], JPN7022000525, 2 May 2017 (2017-05-02), ISSN: 0004701369 *
REGISTRY[ON LINE], JPN7022000526, 2 May 2017 (2017-05-02), ISSN: 0004701370 *
REGISTRY[ON LINE], JPN7022000527, 18 June 2015 (2015-06-18), ISSN: 0004701371 *
REGISTRY[ON LINE], JPN7022000529, 16 February 2014 (2014-02-16), ISSN: 0004701372 *
REGISTRY[ON LINE], JPN7022000530, 31 January 2017 (2017-01-31), ISSN: 0004701366 *
REGISTRY[ON LINE], JPN7022000531, 25 January 2017 (2017-01-25), ISSN: 0004701367 *
TETRAHEDRON, vol. 66, JPN6021020526, 2010, pages 3525 - 3536, ISSN: 0004517364 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512098A (ja) * 2018-01-31 2021-05-13 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
JP7210599B2 (ja) 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
JP2023525860A (ja) * 2020-05-12 2023-06-19 ベイジン・グレートウェイ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド Ｎｍｄａ受容体の活性を調節する化合物、その医薬組成物及び使用
JP7654271B2 (ja) 2020-05-12 2025-04-01 ベイジン・グレートウェイ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド Ｎｍｄａ受容体の活性を調節する化合物、その医薬組成物及び使用

Also Published As

Publication number Publication date
EP3490992B1 (en) 2023-03-22
SG10202101055VA (en) 2021-03-30
CN109937204A (zh) 2019-06-25
CO2019000945A2 (es) 2019-02-08
KR20190033595A (ko) 2019-03-29
AU2021240150A1 (en) 2021-10-28
IL264514B (en) 2021-09-30
IL264514A (en) 2019-02-28
US11530223B2 (en) 2022-12-20
CA3031537A1 (en) 2018-02-08
MX383650B (es) 2025-03-14
CL2019000248A1 (es) 2019-06-21
AU2017306152A1 (en) 2019-01-31
SG11201900443VA (en) 2019-02-27
JP7448766B2 (ja) 2024-03-13
EP3490992A1 (en) 2019-06-05
CN109937204B (zh) 2022-11-25
EA201990424A1 (ru) 2019-08-30
BR112019001768A2 (pt) 2019-06-11
KR102465758B1 (ko) 2022-11-09
US20230312591A1 (en) 2023-10-05
JP2022120019A (ja) 2022-08-17
US20220220119A1 (en) 2022-07-14
US20190177334A1 (en) 2019-06-13
US11299495B2 (en) 2022-04-12
PE20190503A1 (es) 2019-04-10
WO2018026779A1 (en) 2018-02-08
MX2019001319A (es) 2019-07-04
PH12019500202A1 (en) 2019-07-29

Similar Documents

Publication Publication Date Title
JP7448766B2 (ja) スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用
US12084444B2 (en) Spiro-lactam NMDA modulators and methods of using same
US10253032B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
US11376250B2 (en) Spiro-lactam NMDA receptor modulators and uses thereof
JP2019528259A (ja) スピロ−ラクタムｎｍｄａ受容体修飾因子およびその使用
JP2019527235A (ja) スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
CA3089561A1 (en) Spiro-lactam nmda receptor modulators and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220208